- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Pancreatic neuroendocrine tumors (pNET) Extra-pancreatic neuroendocrine tumors (epNET)
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Cabozantinib – July 2025
Cabozantinib; Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
9 July 2025